Cardiac angiosarcoma in the right ventricle treated by surgical resection

Koya Uemura,1 Hiroyuki Sano,1 Hideyuki Takaoka,1 Yutaka Okita2

SUMMARY
Cardiac angiosarcoma is a rare malignant neoplasm, the gold standard treatment is surgical resection. Our patient, an 81-year-old Japanese woman, was admitted to hospital after chest pain over a month-long period. Transthoracic echocardiography (TTE) showed a heterogeneous and irregular mass-like lesion measuring approximately 45×40 mm and arising from the right ventricular free wall. Transesophageal echocardiography showed the lesion had a mobile portion. Considering the possibility of malignancy and a high risk of embolism and obstruction, we performed surgical resection of the tumour. Histological and immunohistochemical findings led to diagnosis of cardiac angiosarcoma. One year after surgery, TTE and CT showed no evidence of recurrence of angiosarcoma.

BACKGROUND
Cardiac angiosarcoma is extremely rare. It has rapid progression and therefore a poor prognosis.1 Patients with cardiac angiosarcoma often exhibit nonspecific symptoms, such as dyspnoea, cough, fatigue and chest pain after the tumour has grown, and diagnosis and treatment are often delayed. Although advances in imaging technology, such as echocardiography, cardiac MRI (cMRI), and CT, have recently played an important role, diagnosis of cardiac angiosarcoma is still very difficult, but treatment strategy must be decided early after diagnosis. Surgical resection for cardiac angiosarcoma is the current gold standard therapeutic method and is reported to improve the prognosis, but recurrence after treatment is not uncommon.2–4 Here, we present an usual case of an elderly woman with a giant primary cardiac angiosarcoma in the right ventricle (RV).

CASE PRESENTATION
An 81-year-old Japanese woman was admitted to our hospital because of chest pain at rest over a month period. She had undergone surgical treatment for papillary thyroid carcinoma 30 years previously and regularly attended a local hospital for treatment of psychiatric problems and hypothyroidism. On admission, her vital signs were unremarkable (blood pressure 125/81 mm Hg, heart rate 78 beats/min, and oxygen saturation 95%). Physical examination showed no heart murmur and there was no jugular venous distention or pedal oedema.

INVESTIGATIONS
An ECG showed a sinus rhythm and an incomplete right bundle branch block. A heterogeneous and irregular mass-like lesion measuring approximately 45×40 mm was detected by transthoracic echocardiography (TTE) on the RV free wall (figure 1). The tricuspid valve contacted the mass-like lesion during diastole. There was a small amount of pericardial effusion. Transesophageal echocardiography showed a part of the mass-like lesion had mobility (figure 2). Contrast-enhanced CT showed a 51 mm lobular mass in the RV that involved the pericardium. Heterogeneous contrast enhancement was visible within the mass (figure 3). On cMRI, the mass lesion in the RV had iso-intensity on T1-weighted imaging, and heterogeneous high signal intensity on T2-weighted imaging (figure 4). Positron emission tomography using 18-fluorodeoxyglucose showed increased accumulation consistent with the anterior lower wall of the RV. It was not considered to be metastatic. Coronary angiography showed a normal coronary artery and we could confirm the RV branch from the right coronary artery into the mass.

Figure 1 Transthoracic echocardiography showed a heterogeneous and irregular mass-like lesion measuring approximately 45×40 mm on the right ventricular free wall. Part of it protruded into the epicardium. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.
laboratory findings and various imaging modalities were inconsistent with these diagnoses.

**TREATMENT**

The mass-like lesion was potentially malignant and had a high risk of embolism and obstruction of the RV from its large size, so we performed surgical resection of the tumour. Cardiopulmonary bypass was established by ascending aortic and innominate venous cannulation in preparation for Glenn surgery in case of haemodynamic failure. After pericardiotomy, the tumour was located from the anterior wall to the apex of the RV (figure 5). The tumour was removed with the adjacent RV wall and then the RV free wall was repaired using an autologous pericardium (figure 6). The chordae tendineae of the tricuspid valve was anchored to the posterior papillary muscle.

Histological findings showed abnormal endothelial cells with large nuclei and good vascularisation. We diagnosed cardiac angiosarcoma. No tumour cells were found at the edges of the area where the tumour had been removed. Immunohistochemical findings showed there were CD31-positive vascular endothelial cells, and the tumour cells invaded the epicardium (figure 7).

**OUTCOME AND FOLLOW-UP**

One year after surgery, TTE and CT showed no evidence of recurrence of angiosarcoma.

**DISCUSSION**

Primary cardiac tumours are very rare with an incidence between 0.001% and 0.3% according to autopsy findings.5 Approximately, 25% of cardiac tumours are malignant, of which cardiac angiosarcoma is the most common, accounting for 30%.6 Cardiac angiosarcoma occurs more frequently in men than in women at a ratio of 2 or 3:1,7 and is more common in younger people, though it can occur at any age.8 9 Although it is found most commonly in the right atrium, it can also be found in the

---

**Figure 2** Transgastric short-axis view of transesophageal echocardiography showed part of the mass-like lesion had mobility. LV, left ventricle; RV, right ventricle.

**Figure 3** Contrast-enhanced CT showed a 51 mm lobular mass spreading laterally from the RV, it spread beyond the pericardium, and heterogeneous contrast enhancement could be seen within the mass. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

**Figure 4** (A, B) Cine images of cardiac MRI (cMRI) for comparison in systolic and diastolic time. The tumour was attached to the anterior wall of the RV. (C) cMRI showed the mass lesion in the RV had heterogeneous high-signal intensity by T2-weighted imaging. LV, left ventricle; RV, right ventricle.

**Figure 5** (A) The tumour was located from the anterior wall to the apex of the RV. (B) The tumour in the anterior wall of the RV behind the anterior leaflet of the tricuspid valve after right atriotomy. RV, right ventricle.
tricuspid valve, RV, pericardium and right coronary artery. Patients with cardiac angiosarcoma often exhibit nonspecific and varied symptoms, including dyspnoea, cough, fatigue, chest pain, weight loss, haemoptysis, embolic events and fever. Based on the TTE finding that the tumour had reached the epicardium, we thought the cause of the chest pain was due to pericardial irritation.

Early diagnosis of cardiac angiosarcoma is very difficult, but it is important to determine the diagnosis and the course of treatment at an early stage because the mean survival of patients with cardiac angiosarcoma without treatment is reported as 3.8±2.5 months. Recent development of non-invasive imaging technologies, such as echocardiography, CT and cMRI, has contributed to the detection and accurate diagnosis of cardiac tumours. Such imaging can also provide more information about the anatomy of the tumour, the presence of metastases, and the distinction between benign and malignant tumours by evaluation of tissue characteristics. Microscopically, angiosarcoma is composed of anaplastic cells derived from vascular components, usually with extensive haemorrhage and necrosis inside the tumour. Contrast-enhanced CT findings of cardiac angiosarcoma therefore show heterogeneous enhancement, and cardiac MRI findings also show heterogeneous T1-weighted and T2-weighted signal intensity patterns.

Tumour biopsies are rarely undertaken recently, but they could be used to make a specific diagnosis. Meanwhile, Rettnar et al reported that endomyocardial biopsy is inadequate for diagnosis and only 50% of specimens of cardiac tumours could be diagnosed in their series. Moreover, biopsies are associated with risks, such as tumour embolisation and bleeding. In the currently reported case, we did not perform biopsy for histological diagnosis before treatment, and surgical tumour resection was chosen instead. Surgical resection of cardiac angiosarcoma is the gold standard for treatment and has been reported as an important prognostic factor. Anatomical considerations, however, such as the location of the tumour occurrence, infiltration of adjacent tissue, and metastasis, are required to prevent incomplete resection from an inadequate view. Furthermore, even when surgical resection of a tumour is performed with negative margins, local recurrence of the tumour is often reported. Considering additional treatment for recurrence, there are options such as chemotherapy and radiation therapy and their combination with surgical resection has been reported to improve the prognosis of patients with cardiac angiosarcoma. Meanwhile, the benefits of such adjuvant chemotherapy and radiotherapy remain unclear, and there are still no standard and accurate regimens. Our patient has had no recurrence of the tumour without the need for adjuvant therapy after surgical resection.

**Case report**

**Learning points**

- Cardiac tumours should be considered as differential diagnoses for a patient with chest pain.
- Treatment strategies for patients with cardiac tumours may be quickly determined by evaluation of various imaging modalities.
- Early diagnosis using various imaging modalities and surgical resection may result in complete resection without recurrence.

**Contributors** All authors conceived the conception and design of the case report and discussed planning, analysis and interpretation of data, participated in interpretation of the results and writing of the report. KU, HS and YO have been involved in the patient’s care. HS supervised the project. HT and YO performed revising it critically for important intellectual content. All authors approved the final version, and agreed to be accountable for the article and to ensure that all questions regarding the accuracy or integrity of the article are investigated and resolved.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**

1. Pigott C, Welker M, Khosa P, et al. Improved outcome with multimodality therapy in primary cardiac angiosarcoma. *Nat Clin Pract Oncol* 2008;5:112–5.
2. Nakamichi T, Fukuda T, Suzuki T, et al. Primary cardiac angiosarcoma: 53 months’ survival after multidisciplinary therapy. *Ann Thorac Surg* 1997;63:1160–1.
3. Kim MP, Corea AM, Blackmon S, et al. Outcomes after right-side heart sarcoma resection. *Ann Thorac Surg* 2011;91:770–6.
4. Oh SJ, Yeom SY, Kim K-H. Clinical implication of surgical resection for the rare cardiac tumors involving heart and great vessels. *J Korean Med Sci* 2013;28:717–24.
5. Patel J, Sheppard MN. Pathological study of primary cardiac and pericardial tumours in a specialist UK centre: surgical and autopsy series. *Cardiovasc Pathol* 2010;19:343–52.
6. Hoffmeier A, Sinderenn JR, Scheld HH, et al. Cardiac tumors—diagnosis and surgical treatment. *Dtsch Arztebl Int* 2014;111:205–11.
7. Antonouzo L, Rotella V, Mazzoni F, et al. Primary cardiac angiosarcoma: a fatal disease. *Case Rep Med* 2009;2009:1–4.
8. Hamidi M, Moody JS, Weigel TL, et al. Primary cardiac sarcoma. *Ann Thorac Surg* 2010;90:176–81.
9. Best AK, Dobson RL, Ahmad AR. Best cases from the AFIP: cardiac angiosarcoma. *Radiographics* 2003;23 Spec No:S141–5.
10. Hoey ETD, Mankad K, Puppala S, et al. MRI and CT appearances of cardiac tumours in adults. *Clin Radiol* 2009;64:1214–30.
11. Simpson L, Kumar SK, Okuno SH, et al. Malignant primary cardiac tumors: review of a single institution experience. *Cancer* 2008;112:2440–6.
12. Kim CH, Dancer JT, Coffey D, et al. Clinicopathologic study of 24 patients with primary cardiac sarcomas: a 10-year single institution experience. *Hum Pathol* 2008;39:933–8.
13. Butany J, Yu W. Cardiac angiosarcoma: two cases and a review of the literature. *Can J Cardiol* 2000;16:197–205.
Case report

14 Motwani M, Kidambi A, Herzog BA, et al. MR imaging of cardiac tumors and masses: a review of methods and clinical applications. *Radiology* 2013;268:26–43.

15 Donsbeck AV, Ranchere D, Coindre JM, et al. Primary cardiac sarcomas: an immunohistochemical and grading study with long-term follow-up of 24 cases. *Histopathology* 1999;34:295–304.

16 Yu J-F, Cui H, Ji G-M, et al. Clinical and imaging manifestations of primary cardiac angiosarcoma. *BMC Med Imaging* 2019;19:16.

17 Rettmar K, Stierle U, Sheikhzadeh A, et al. Primary angiosarcoma of the heart. Report of a case and review of the literature. *Jpn Heart J* 1993;34:667–83.

18 Cataldi MS. Primary cardiac angiosarcoma. Revista da Socerj 2006;19:87–91.

19 Riles E, Gupta S, Wang DD, et al. Primary cardiac angiosarcoma: a diagnostic challenge in a young man with recurrent pericardial effusions. *Exp Clin Cardiol* 2012;17:39–42.

20 Sinatra R, Brancaccio G, di Gioia CRT, et al. Integrated approach for cardiac angiosarcoma. *Int J Cardiol* 2003;88:301–4.

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:
- Submit as many cases as you like
- Enjoy fast sympathetic peer review and rapid publication of accepted articles
- Access all the published articles
- Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow.